Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Rhea-AI Summary

Citius Pharmaceuticals (Nasdaq: CTXR) reported first-quarter fiscal 2026 results and the first reported revenue after the December 2025 commercial launch of LYMPHIR. Consolidated revenue was $3.9 million from initial U.S. distributor sales. Cash totaled $7.7 million and the company generated approximately $20.9 million net proceeds from equity financings. R&D expense declined to $1.6 million, general and administrative expense was $5.7 million, stock-based compensation rose to $4.3 million, and net loss narrowed to $8.2 million (−16% year-over-year). The company reported early physician adoption, international named-patient agreements, and ongoing investigator-initiated studies exploring LYMPHIR combinations.

Positive

• First revenue of $3.9M from LYMPHIR launch (Dec 2025)
• Raised $20.9M net proceeds from equity financings in the quarter
• Net loss narrowed to $8.2M, down ~16% year-over-year

Negative

• Stock-based compensation increased to $4.3M (+72% vs prior year)
• R&D spending declined to $1.6M (reflecting reduced clinical activity)

Key Figures

First-quarter revenue: $3.9 million Cash and equivalents: $7.7 million Equity financing proceeds: $20.9 million +5 more

8 metrics

First-quarter revenue $3.9 million Initial LYMPHIR sales, fiscal Q1 2026

Cash and equivalents $7.7 million Balance as of December 31, 2025

Equity financing proceeds $20.9 million Net proceeds from quarter’s equity financings

R&D expenses $1.6 million vs $2.1 million Fiscal Q1 2026 vs prior-year period

G&A expenses $5.7 million vs $5.4 million Fiscal Q1 2026 vs prior-year period

Stock-based compensation $4.3 million vs $2.5 million Fiscal Q1 2026 vs prior-year period

Net loss $8.2 million vs $9.8 million Net loss applicable to common stockholders, Q1 2026 vs prior year

EPS $(0.41) vs $(1.30) Net loss per share, Q1 2026 vs prior-year period

Market Reality Check

Price: $1.22 Vol: Price up 4.42% with volum...

high vol

$1.22 Last Close

Volume Price up 4.42% with volume 403,626 vs 20-day average 193,566 (about 2.09x typical activity). high

Technical Shares at $1.18, trading below the 200-day moving average of $1.61 and well under the $6.19 52-week high.

Peers on Argus

CTOR gained 4.42% while close peers showed mixed moves (e.g., IRWD up 3.83%, DER...

1 Up 1 Down

CTOR gained 4.42% while close peers showed mixed moves (e.g., IRWD up 3.83%, DERM down 4.22%, BIOA down 3.17%). With peers moving in both directions and momentum data split (SXTC down 3.42%, IRWD up 1.30%), the action appears stock-specific rather than sector-driven.

Historical Context

5 past events · Latest: Feb 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 11	EU access agreement	Positive	+0.0%	Exclusive Uniphar deal to expand LYMPHIR access across European territories.
Dec 23	FY25 earnings	Neutral	+1.6%	Fiscal 2025 results, $36M financings and LYMPHIR U.S. launch support disclosed.
Dec 23	FY25 earnings	Positive	+1.6%	LYMPHIR FDA approval, U.S. launch, 19-market access and reimbursement milestones.
Dec 10	Financing closed	Negative	-2.6%	Closing of $18M registered direct and private placement with new shares and warrants.
Dec 09	Financing announced	Negative	+6.4%	Announcement of $18M at-the-market offering with share and warrant issuance terms.

Pattern Detected

Recent news has produced mixed reactions: financing announcements have seen both gains and losses, while operational updates around LYMPHIR and earnings have generally coincided with modestly positive or flat price moves.

Recent Company History

Over the last several months, CTOR focused on financing and commercializing LYMPHIR. In December 2025, the company announced and then closed an $18 million registered direct and private placement, involving new shares and repriced warrants at $1.09. Fiscal 2025 results for both Citius Oncology and Citius Pharmaceuticals highlighted the December U.S. launch of LYMPHIR and expanded access via 19 international named patient markets, NCCN Category 2A status, and a permanent HCPCS J-code. On February 11, 2026, CTOR reported a European distribution agreement with Uniphar. Today’s first reported LYMPHIR revenue and quarterly results build directly on those commercialization steps.

Market Pulse Summary

This announcement marks CTOR’s shift to a commercial-stage profile, with initial LYMPHIR revenue of ...

Analysis

This announcement marks CTOR’s shift to a commercial-stage profile, with initial LYMPHIR revenue of $3.9 million, cash of $7.7 million, and $20.9 million raised via equity financings in the quarter. Investors may track trends in quarterly LYMPHIR sales, operating expenses—including R&D at $1.6 million and G&A at $5.7 million—and net loss of $8.2 million as indicators of scalability. Progress of late-stage assets Mino-Lok and Halo-Lido, plus international access initiatives, also remain key watch points.

Key Terms

named patient programs, ai-enabled commercial platform, phase i, car-t therapy

4 terms

named patient programs regulatory

"patient access to LYMPHIR utilizing Named Patient Programs (NPPs) where permitted"

Named patient programs are arrangements that allow patients to access experimental or unapproved medicines outside of regular clinical trials, often through special approvals. They matter to investors because they can signal a company's efforts to bring new treatments to market and may impact perceptions of future sales potential or regulatory progress. These programs can also influence a company's reputation and relationships within the healthcare industry.

ai-enabled commercial platform technical

"Citius Oncology deployed an AI-enabled commercial platform to support targeted physician"

An ai-enabled commercial platform is a software product businesses use to deliver or improve commercial activities that embeds artificial intelligence to automate, analyze, or optimize tasks such as customer interactions, sales, supply chains, or personalization. Investors care because AI can allow the platform to serve more customers at lower cost and create a competitive edge—like replacing repetitive manual work with a smart assistant—so revenue and profit potential hinge on data quality, scalability and ongoing operating costs.

phase i medical

"Preliminary topline data from two investigator-initiated Phase I combination studies"

A Phase I clinical trial is the first stage of testing a new drug or treatment in humans, focused mainly on safety and finding an appropriate dose by studying a small group of volunteers or patients. Investors watch Phase I results because they reveal early signs of safety, tolerability and how the body handles the treatment—information that helps gauge development risk and the likelihood and timing of later, larger trials that drive a drug’s value, much like a test drive reveals whether a prototype is worth further investment.

car-t therapy medical

"incorporation as part of lymphodepletion regimens prior to CAR-T therapy;"

CAR-T therapy is a type of medical treatment that uses a patient's own immune cells, specially modified to better recognize and attack cancer cells. For investors, it represents a significant advancement in cancer care, with the potential to transform treatment options and generate substantial demand, making companies involved in its development and production potentially valuable in the healthcare industry.

AI-generated analysis. Not financial advice.

Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results

CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter ended December 31, 2025, and provided a business update, including progress at its majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR).

"I am thrilled to report that we have successfully transitioned to a revenue generating company following Citius Oncology's December 2025 launch of LYMPHIR. We recorded $3.9 million in revenue during the quarter, reflecting the initial sales at Citius Oncology's nationwide network of distributors. This milestone is the result of years of focused execution designed to translate innovation into tangible value for the cutaneous T-cell community and Citius stakeholders alike. I congratulate the entire Citius team on an outstanding effort to bring LYMPHIR to market," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology and Citius Pharma.

"While we are still in the early stages of the launch, we expect momentum to build as we continue to stand up the full commercial organization and more fully deploy our technology-driven platform to expand patient access and drive market penetration. Looking ahead, we see multiple avenues for growth, including encouraging early signals from investigator-initiated studies, opportunities to expand access in international markets, and the potential to build a durable oncology franchise. Most importantly, LYMPHIR now offers patients living with cutaneous T-cell lymphoma a meaningful new treatment option and a more hopeful future," added Mazur.

"We remain committed to financial stewardship to sustain this momentum, and focused execution to advance our late-stage pipeline, which includes Mino-Lok and Halo-Lido. Our goal remains to serve our community with first-in-class critical care products, and in so doing maximize long-term shareholder value," concluded Mazur.

Business Highlights and Subsequent Developments

• Commercial inflection achieved through majority-owned subsidiary: Citius Oncology successfully launched LYMPHIR™ (denileukin diftitox-cxdl) in the U.S. in December 2025 for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) following at least one prior systemic therapy;
• Early physician adoption underway: Initial specialty distributor sales were completed nationwide, enabling product availability across U.S. treatment centers. Patients have begun receiving LYMPHIR at leading cancer centers;
• Commercial execution supported by technology: Citius Oncology deployed an AI-enabled commercial platform to support targeted physician engagement and efficient penetration of a highly concentrated prescriber base in this rare oncology market;
• International patient access advancing: Agreements have been negotiated with regional partners to enable patient access to LYMPHIR utilizing Named Patient Programs (NPPs) where permitted in territories throughout European and the Middle East;
• Continued support of promising upside opportunities for LYMPHIR: Preliminary topline data from two investigator-initiated Phase I combination studies evaluating the potential to expand clinical utility and future label expansion opportunities. include:
• use in combination with pembrolizumab in patients with recurrent solid tumors;
• incorporation as part of lymphodepletion regimens prior to CAR-T therapy;
• Late-stage pipeline progress maintained: Citius Pharma continues to advance Mino-Lok®, an antibiotic lock solution to salvage catheters when treating catheter-related bloodstream infections, and Halo-Lido (CITI-002), a topical prescription formulation for hemorrhoids. The Company remains engaged with the FDA regarding both programs.

First Quarter 2026 Financial Highlights

• Cash and cash equivalents totaled $7.7 million as of December 31, 2025;
• Generated net proceeds of approximately $20.9 million from equity financings during the quarter, including capital raised at both Citius Pharma and Citius Oncology;
• Consolidated revenue was $3.9 million, reflecting initial U.S. sales of LYMPHIR at Citius Oncology;
• Research and development expenses were $1.6 million, compared to $2.1 million in the prior-year period, reflecting reduced clinical development activity;
• General and administrative expenses totaled $5.7 million, compared to $5.4 million in the prior-year period;
• Stock-based compensation expense totaled $4.3 million, compared to $2.5 million in the prior-year period; and,
• Net loss applicable to common stockholders was $8.2 million, or $(0.41) per share, compared to a net loss of $9.8 million, or $(1.30) per share, in the prior-year period.

About Citius Pharmaceuticals, Inc. 
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 74.8% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma's late-stage pipeline also includes Mino-Lok^®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.

About Citius Oncology, Inc.
Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In December 2025, Citius Oncology launched LYMPHIR, approved by the FDA for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.

Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: our ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream; the estimated markets for LYMPHIR and our product candidates and the acceptance thereof by any market; our ability to secure strategic partnerships and expand international access to LYMPHIR; our ability to use the latest technology to support our commercialization efforts for LYMPHIR; physician and patient acceptance of LYMPHIR in a competitive treatment landscape; the ability of LYMPHIR and our product candidates to impact the quality of life of our target patient populations; our need for substantial additional funds and our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to maintain Nasdaq's continued listing standards; our reliance on third-party logistics providers, distributors, and specialty pharmacies to support commercial operations; our ability to educate providers and payers, secure adequate reimbursement, and maintain uninterrupted product supply; post-marketing requirements and ongoing regulatory compliance related to LYMPHIR; risks relating to the results of research and development activities, including those from any new pipeline assets; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; government regulation; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov, including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2025, filed with the SEC on December 23, 2025. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113

Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com 

-- Financial Tables Follow –

 

CITIUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
		December 31,				September 30,
		2025				2025
ASSETS
Current Assets:
Cash and cash equivalents		$	7,721,393			$	4,252,290
Accounts receivable, net of allowances			4,049,111				-
Inventory			22,639,342				22,286,693
Prepaid expenses			3,535,287				1,395,490
Total Current Assets			37,945,133				27,934,473
Operating lease right-of-use asset, net			835,177				818,694
Deposits			38,062				38,062
In-process research and development, net of accumulated amortization			92,226,562				92,800,000
Goodwill			9,346,796				9,346,796
Total Other Assets			101,611,420				102,184,858
Total Assets		$	140,391,730			$	130,938,025
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable		$	11,021,412			$	13,693,692
License payable			18,250,000				22,650,000
Accrued expenses			4,693,307				4,190,253
Accrued compensation			3,094,395				3,292,447
Note payable			1,000,000				1,000,000
Operating lease liability			148,006				88,348
Total Current Liabilities			38,207,120				44,914,740
Deferred tax liability			8,035,000				7,770,760
Operating lease liability – noncurrent			681,640				724,925
Total Liabilities			46,923,760				53,410,425
Commitments and Contingencies
Stockholders' Equity:
Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued      and outstanding			-				-
Common stock - $0.001 par value; 250,000,000 shares authorized; 22,376,427 and      18,067,744 shares issued and outstanding at December 31, 2025 and September      30, 2025, respectively			22,376				18,068
Additional paid-in capital			326,960,700				306,336,239
Accumulated deficit			(247,024,914)				(238,804,129)
Total Citius Pharmaceuticals, Inc. Stockholders' Equity			79,958,162				67,550,178
Non-controlling interest			13,509,808				9,977,422
Total Equity			93,467,970				77,527,600
Total Liabilities and Equity		$	140,391,730			$	130,938,025

 

CITIUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 (Unaudited)
		Three Months Ended
		December 31,				December 31,
		2025				2024
Revenue		$	3,944,111				—
Cost of revenues			(789,208)				—
Gross Profit			3,154,903				—
Operating Expenses
Research and development			1,599,719				2,127,038
Amortization of in-process research and development			573,438				—
General and administrative			5,720,727				5,387,752
Stock-based compensation – general and administrative			4,280,227				2,524,824
Total Operating Expenses			12,174,111				10,039,614
Operating Loss			(9,019,208)				(10,039,614)
Other Income (Expense)
Interest income			45,097				22,608
Interest expense			(155,538)				—
Total Other Income (Expense)			(110,441)				22,608
Loss before Income Taxes			(9,129,649)				(10,017,006)
Income tax expense			264,240				264,240
Net Loss			(9,393,889)				(10,281,246)
Net loss attributable to non-controlling interest			1,173,104				513,000
Net loss applicable to common stockholders		$	(8,220,785)			$	(9,768,246)
Net Loss Per Share - Basic and Diluted		$	(0.38)			$	(1.30)
Weighted Average Common Shares Outstanding
Basic and diluted (include pre-funded warrants from the October 2025 offering)			21,495,274				7,492,460

 

CITIUS PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED DECEMBER 31, 2025 AND 2024 (Unaudited)
		2025				2024
Cash Flows From Operating Activities:
Net loss		$	(9,393,889)			$	(10,281,246)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense			4,280,227				2,524,824
Issuance of common stock for services			107,510				—
Issuance of common stock warrant			68,597				—
Amortization of in-process research and development			573,438				—
Amortization (accretion) of operating lease right-of-use asset			(16,483)				54,835
Deferred income tax expense			264,240				264,240
Changes in operating assets and liabilities:
Accounts receivable, net of allowances			(4,049,111)				—
Inventory			(352,649)				(6,112,603)
Prepaid expenses			(2,139,797)				(145,739)
Accounts payable			(2,672,280)				2,436,909
Accrued expenses			503,054				6,225,151
Accrued compensation			(198,052)				366,073
Operating lease liability			16,373				(58,296)
Net Cash Used In Operating Activities			(13,008,822)				(4,725,852)
Cash Flows From Investing Activities:
License fee payments			(4,400,000)				—
Net Cash Used in Investing Activities			(4,400,000)				—
Cash Flows From Financing Activities:
Net proceeds from common stock offerings			20,877,925				2,574,051
Net Cash Provided By Financing Activities			20,877,925				2,574,051
Net Change in Cash and Cash Equivalents			3,469,103				(2,151,801)
Cash and Cash Equivalents - Beginning of Period			4,252,290				3,251,880
Cash and Cash Equivalents - End of Period		$	7,721,393			$	1,100,079
Supplemental Disclosures of Cash Flow Information and Non-cash Transactions:
Interest paid		$	14,460			$	—

View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-announces-first-reported-revenue-following-successful-launch-of-lymphir-302687092.html

SOURCE Citius Pharmaceuticals, Inc.

FAQ

How much revenue did Citius Pharmaceuticals (CTXR) report from the LYMPHIR launch in Q1 2026?

Citius reported $3.9 million in consolidated revenue tied to LYMPHIR initial U.S. sales. According to the company, these sales reflect December 2025 launches through a nationwide distributor network at Citius Oncology and initial patient treatments at major centers.

What is Citius Pharmaceuticals' (CTXR) cash position and recent financing as of December 31, 2025?

Citius held $7.7 million in cash and cash equivalents as of December 31, 2025. According to the company, it also generated approximately $20.9 million in net proceeds from equity financings during the quarter to support operations.

Did Citius Pharmaceuticals (CTXR) narrow its net loss in Q1 2026 and by how much?

Yes. Net loss applicable to common stockholders was $8.2 million, improved from $9.8 million a year earlier. According to the company, this represents a roughly 16% year-over-year reduction in net loss per reported results.

What commercial traction has LYMPHIR achieved since its December 2025 U.S. launch (CTXR/CTOR)?

LYMPHIR achieved initial nationwide specialty distributor sales and early physician adoption at leading cancer centers. According to the company, the rollout includes an AI-enabled commercial platform and named-patient agreements for select international territories.

What material expense changes did Citius Pharmaceuticals (CTXR) report in Q1 2026?

R&D expense decreased to $1.6 million, while stock-based compensation rose to $4.3 million. According to the company, R&D reduction reflects lower clinical activity and stock-based pay increased versus the prior-year period.